Dramatic Impact of Centralization and a Multidisciplinary Bladder Cancer Program in Reducing Mortality: The CABEM Project

PURPOSE Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a complex treatment. In Brazil, as in most developing countries, data are scarce, but mortality seems exceedingly high. We have created a centralization program involving a multidisciplinary clinic in a region comprising seven municipalities. The aim of this study is to evaluate the impact of […]

SIU 2021: AUA Lecture: 2021 Renal Mass Guideline Update 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a plenary session with the AUA lecture provided by Dr. Sam Chang discussing the 2021 AUA Guideline for renal masses and localized cancer, specifically evaluation, management, and follow-up.1,2 Dr. Chang notes that the AUA guidelines focus on the evaluation and management of clinically localized sporadic renal […]

SIU 2021: Immune-related Biomarkers of Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Murat Bozlu discussing immune-related biomarkers of bladder cancer. Dr. Bozlu started his presentation by noting that bladder cancer makes up 7% of new cancer cases amongst males, accounting for 4% of cancer mortalities. However, […]

SIU 2021: Molecular Subtypes of Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Seth Lerner discussing molecular subtypes of bladder cancer. Dr. Lerner started by highlighting seminal work from his group that used the bladder cancer TCGA dataset to provide a comprehensive molecular characterization of muscle invasive […]

SIU 2021: Serum Biomarkers in Invasive Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Sia Daneshmand discussing serum biomarkers in invasive bladder cancer. Dr. Daneshmand started by emphasizing that unfortunately, up to 50% of patients after radical cystectomy experience disease recurrence within five years of surgery. Furthermore, there […]

X